• Home
  • Study Details
By physician referral or invitation only

Treatment Satisfaction with Avatrombopag in Chronic ITP patients

Current treatments of Chronic ITP include Eltrombopag, Romiplostim, and Avatrombopag (DOPTELET). However, Doptelet provides unique benefits in that it can be orally taken as a pill once daily without restrictions on diet or requiring a provider unlike the other available treatments. This study aims to characterize the switch from other available treatments to doptelet and measure the safety, efficacy, and patient reported satisfaction with avatrombopag for 90 days.

Age & Gender

  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive

Contact the Team


Thank you for your interest, but this study is recruiting by invitation only.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Raj Kasthuri

Study Type

Clinical or Medical

Study Topics

Blood Conditions
Chronic Conditions
Genetics and Genetic Disorders
Immune System/Infections
Rare Diseases
Wellness and Lifestyle

IRB Number




Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.


  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research